[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcranial-alternating-current-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcranial-alternating-current-stimulation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,65,94,120,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100631830","transcranial-alternating-current-stimulation-in-frontotemporal-dementia-100631830",false,"NCT07505784","Transcranial Alternating Current Stimulation in Frontotemporal Dementia","Cross-over Study to Evaluate the Safety, Tolerability, and Clinical Efficacy of Transcranial Alternating Current Stimulation (tACS) in Patients With Frontotemporal Dementia","BetaTACSFTD","Inclusion Criteria:\n\n* Male or female subjects aged over 40 years at the time of signing the informed consent form;\n* Presence of a clinical diagnosis of Frontotemporal Dementia according to clinical criteria (Rascovsky et al., 2011; Gorno-Tempini et al., 2011).\n\nExclusion Criteria:\n\n* Age younger than that stated in the inclusion criterion;\n* Inability to understand;\n* Contraindications for tACS and TMS: cardiac pacemaker carriers and metal implants that are not compatible with electric or magnetic fields, history of epilepsy, current pregnancy (Safety Questionnaire)","ALL","40 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation (tACS) in patients with Frontotemporal Dementia (FTD).\n\nIn addition to typical symptoms, FTD also present alterations in brain oscillations. In animal models of neurodegeneration, restoration of oscillations via neuronal \"entrainment\" phenomena has demonstrated a significant reduction in toxic protein accumulation, resulting in improved cognitive function.\n\ntACS is a neurophysiological noninvasive method of neuromodulation increasingly studied for its therapeutic potential. It has been shown to safely modulate the oscillatory frequencies underlying multiple cognitive functions, including verbal memory, perception, and working memory.\n\nIn light of this evidence, it is proposed to apply a single-session treatment of β-tACS stimulation in patients with FTD and to evaluate its clinical effects, oscillatory modifications by EEG, and changes in neurophysiological indices such as short intracortical inhibition (SICI) and intracortical facilitation (ICF), both compromised in the disease.\n\nThe study has a cross-over design (multicenter, randomized, placebo-controlled and double-blind), with FTD patients randomly assigned to one of the two arms: i) Group 1, who will receive a real tACS session first (1h); ii) Group 2, who will instead undergo a sham tACS session (1h). In the next phase (cross-over), one week after the first phase, the groups will reverse the treatment: Group 1 will receive tACS sham and Group 2 will receive real tACS.\n\nThe main objectives of the study are: \\[1\\] to evaluate the safety and tolerability of the single tACS treatment session; \\[2\\] to investigate the effects of the protocol on (short-term) cognitive performance in patients with FTD; \\[3\\] to verify intervention-induced changes in brain synchronization; \\[4\\] to evaluate changes in neurophysiological indices following treatment; and \\[5\\] evaluate any predictors of efficacy.",[27,28],"Transcranial Alternating Current Stimulation","Frontotemporal Dementia (FTD)","RECRUITING","2026-03-26",{"date":32,"type":33},"2026-04-01","ACTUAL",{"date":35,"type":33},"2026-02-03",{"date":37,"type":21},"2027-02",{"name":39,"class":40},"IRCCS Centro San Giovanni di Dio Fatebenefratelli","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100621834","transcranial-alternating-current-stimulation-in-lewy-body-dementia-100621834","NCT07375771","Transcranial Alternating Current Stimulation in Lewy Body Dementia","Interventional Study to Evaluate the Effectiveness of Transcranial Alternating Current Stimulation (tACS) on Cognitive Performance in Patients With Lewy Body Dementia","TACSDLB2","Inclusion Criteria:\n\n* Male or female subjects aged over 18 at the time of signing the informed consent form;\n* Presence of a clinical diagnosis of Lewy body dementia according to clinical criteria (McKeith et al., 2017)\n\nExclusion Criteria:\n\n* Age younger than that stated in the inclusion criteria;\n* Incapacity to understand;\n* Contraindications for tACS and TMS: patients with cardiac pacemakers and metal implants that are not compatible with electric or magnetic fields, history of epilepsy, current pregnancy (Safety questionnaire)","18 Years",{"count":52,"type":21},40,[24],"The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation (tACS) in patients with Lewy Body Dementia (DLB).\n\nIn neurodegenerative diseases, like DLB, the process of neurodegeneration is accompanied by a significant alteration in oscillatory activity.\n\ntACS is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that uses a mild electrical current. Recent studies have demonstrated the safety and efficacy of this method in modulating the natural brain oscillation frequencies underlying multiple cognitive processes, such as verbal memory, perception, and working memory. Preliminary data show that single stimulation with occipital α-tACS results in a significant improvement in visuospatial abilities and executive functions in patients wih DLB.\n\nThe study is double blind, randomised and placebo-controlled, participants will be randomised into two groups: group 1, participants will receive real tACS for 2 weeks, from Wednesday to Tuesday (5 sessions\u002Fweek, lasting approximately 60 minutes each); and group 2, participants will receive placebo tACS for 2 weeks (5 sessions\u002Fweek, lasting approximately 60 minutes each).\n\nVisits will take place at the beginning of the study (T00), after 2 weeks (T02), and 12 weeks (T12, follow-up). During each visit, participants undergo the following procedures: (i) blood sampling, (ii) clinical and neuropsychological assessment, (iii) EEG, and (iv) TMS-EEG. The occurrence of adverse events will be monitored throughout the duration of the study. Specific biomarker analyses will be performed on the blood samples to study the pathophysiological mechanisms of the disease and the effect of the experimental intervention.",[56,27],"Lewy Body Dementia (LBD)","2026-01-21",{"date":59,"type":33},"2026-01-29",{"date":61,"type":33},"2025-10-01",{"date":63,"type":21},"2030-09",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100614675","closed-loop-transcranial-alternating-current-stimulation-for-the-treatment-of-major-depressive-disorder-100614675","NCT07282678","Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder","Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder: Double-Blind, Controlled Randomized Multicenter Clinical Trial","Inclusion Criteria:\n\n1. ≥ 22 years of age;\n2. with at least moderate symptom severity (HAM-D17 ≥ 17);\n3. who are currently in a depressive episode;\n4. who have used at least 1 antidepressant in the current or previous episode, but have not found adequate symptom relief or who were not able to tolerate medication side effects;\n5. who, for 6 weeks prior to enrollment, are either;\n\n   * not taking antidepressant medication, or:\n   * are taking a stable psychiatric medication regimen with one or more stable antidepressant medication dose(s)\n6. if currently engaged in depression-focused psychotherapy, have maintained stable frequency of therapy for at least 8 weeks prior to enrollment and agree to continue the same regimen throughout study participation;\n7. are able and willing to comply with the protocol and follow up schedule and protocol, in the opinion of the investigator;\n8. who understand English and are able to provide written informed consent;\n9. who are currently under the care of a psychiatric clinician or a primary care physician for major depressive disorder, and who agree to promptly inform the study staff of any change of psychiatric or mental health providers during study participation;\n10. who agree to allow any and all forms of communication between the investigators\u002Fstudy staff and their current or past (within 2 years) healthcare providers;\n11. who agree to provide the names and verifiable contact information (email and mailing addresses, mobile and\u002For land-line phone numbers, as applicable) for at least two persons (≥ age 18) who reside within a 60-minute drive of their residence and whom the research staff are at liberty to contact, as they deem necessary, to ensure participant safety for the duration of study participation;\n\nExclusion Criteria:\n\n1. Subjects with current \u002F past six months use of an external stimulation device for MDD, including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain or cranial nerve stimulation;\n2. Subjects with (lifetime) history of failure to response to an adequate trial of ECT, TMS, or implanted vagus nerve stimulation;\n3. Subjects who currently receive esketamine, ketamine, or psilocybin treatment\n4. Subjects who are pregnant or of childbearing potential and not using adequate contraception, as determined by the investigator;\n5. Subjects who are breastfeeding.\n6. Subjects whose current depressive episode had onset within 6 months post-partum;\n7. Presence of active skin disorder on the forehead that could be exacerbated by stimulation electrodes in the opinion of the investigator.\n8. Subjects with clinical or historical features which, in the opinion of the investigator, make them an inappropriate candidate for participation in this trial;\n9. Subjects whose current depressive episode has not responded to 3 or more adequate trials of FDA approved antidepressant medications;\n10. Subjects with current suicidal ideation with plan or intent, or suicidal behavior or preparation in the past 3 months, as determined by CSSRS assessment or by the Investigator;\n11. Subjects with a history of epilepsy or unexplained seizures, as determined by the Investigator;\n12. Subjects with a diagnosis or clinical history suggestive of bipolar disorder, hypomania, mania, or psychosis, as determined by the Investigator.\n13. Subjects currently participating, or intending to participate (during the next 3 months) in another study involving an investigational drug or device treatment that, in the opinion of the investigator, could impact symptoms of MDD or use of the investigational device;\n14. Subjects with a history of intracranial surgery;\n15. Subjects with implanted neurostimulators, nonremovable or implanted electrical devices or intracranial metal objects, with the exception of dental metal;\n16. Subjects with cognitive impairment or memory disorders, which, in the opinion of the investigator, could impact their ability to comply with study requirements;\n17. Subjects currently meeting diagnostic criteria for obsessive compulsive disorder;\n18. Subjects who meet DSM-V criteria for moderate\u002Fsevere alcohol use disorder or other substance use disorders (except tobacco\u002Fnicotine) within the past 6 months as confirmed by the DIAMOND interview;\n19. Subjects who meet DSM-V criteria for moderate\u002Fsevere cannabis use disorder (CUD) within the past 6 months as confirmed by the DIAMOND interview. Subjects with recreational or prescription use (including medical marijuana cards) not considered moderate to severe CUD will be included.\n20. Subjects with a current neurological condition or disease which, in the opinion of the investigator, is likely to manifest a depressive syndrome or symptoms that would substantially confound the diagnosis or serial assessment of major depressive disorder.","22 Years",{"count":74,"type":21},214,[24],"The purpose of this research study is to investigate a closed-loop transcranial alternating current stimulation (tACS) device to evaluate its ability to reduce symptoms of major depressive disorder",[78,27],"Depression - Major Depressive Disorder",[80,81,82,27],"tACS","Depression","Major Depressive Disorder","NOT_YET_RECRUITING","2025-12-12",{"date":86,"type":33},"2025-12-17",{"date":88,"type":21},"2025-12",{"date":90,"type":21},"2028-01",{"name":92,"class":93},"Pulvinar Neuro, LLC","INDUSTRY",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":41},"100599698","assessment-of-transcranial-alternating-current-stimulations-clinical-efficacy-in-treating-cognitive-impairment-of-idiopathic-inflammatory-demyelinating-diseases-100599698","NCT07087873","Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases","TACS-CI-IIDDs","Inclusion Criteria:\n\n* Age: 18-60 years old.\n* Diagnosis: Patients with neuromyelitis optica spectrum disease, multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system that meet the diagnostic criteria.\n* Medications have been stable for at least three months.\n\nExclusion Criteria:\n\n* Recurrence has been recorded in the past 3 months.\n* Have a pacemaker or other metal implant in the body.\n* Impaired skin integrity at the site of electrode placement.\n* Previous organic brain disease such as epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infection.\n* Combined with severe or unstable organic diseases, such as heart, liver and kidney and other organ dysfunction.\n* Pregnant or lactating women, those who are planning to become pregnant in the near future.\n* Patient compliance is poor.\n* In the opinion of the investigator, there is a situation that is not suitable to participate in this study.","60 Years",{"count":103,"type":21},128,[24],"This study aims to explore the imaging and electrophysiological characteristics of idiopathic inflammatory demyelinating diseases (IIDDs), and their correlation with clinical manifestations. It also evaluates the effectiveness of transcranial electrical stimulation in alleviating clinical symptoms of IIDDs patients, and analyzes the key factors affecting the treatment efficacy. By uncovering the overall and individual characteristics of IIDDs, this study seeks to enhance therapeutic outcomes through personalized neuromodulation programs. The findings will provide a basis for applying non-invasive brain stimulation (NIBS) in IIDDs treatment and offer new ideas for future personalized medicine approaches.",[107,108,109,110,27],"Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System","MS (Multiple Sclerosis)","NMOSD","Acute Disseminated Encephalomyelitis","2025-07-24",{"date":113,"type":33},"2025-07-28",{"date":115,"type":33},"2025-05-30",{"date":117,"type":21},"2027-10-31",{"name":119,"class":40},"Xuanwu Hospital, Beijing",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":41},"100584391","efficacy-of-hi-tacs-for-schizophrenia-negative-symptoms-100584391","NCT06888726","Efficacy of Hi-tACS for Schizophrenia Negative Symptoms","Efficacy of High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) in Treating Negative Symptoms of Schizophrenia","Inclusion Criteria:\n\n* Han Chinese population;\n* Age ≥ 18 years;\n* Education level ≥ 6 years, able to fill out questionnaires on their own, and having sufficient audiovisual level to complete the necessary examinations;\n* Meets DSM-5 diagnostic criteria for schizophrenia as assessed by MINI 7.0;\n* Residual negative symptoms, with at least one item ≥2 on the negative subscale of PANSS (N1-N7);\n* Taking second-generation atypical antipsychotic medication, with no medication or dosage adjustments in the last two weeks\n* Patients and guardians agreed to participate in the study and signed an informed consent form.\n\nExclusion Criteria:\n\n* Meets DSM-5 diagnostic criteria for other mental disorders;\n* Total score ≥19 on the PANSS positive subscales (P1-P7) ;\n* Severe negative symptoms that prevent the patient from completing the required assessments and interventions;\n* Serious physical or central nervous system disease (intracranial infection, intracranial tumor, presence of metal objects in the skull; epilepsy, seizures; history of hydrocephalus or central nervous system tumors; with implanted electronic devices; serious cardiac disease and fitted with a pacemaker, etc.);\n* Impaired skin integrity at the site of electrode placement or hypersensitivity to electrode gels or adhesives;\n* Mental retardation (Wechsler Adult Intelligence Scale WAIS \\\u003C70) and\u002For severe cognitive impairment (Brief Mental State Examination MMSE \\\u003C24);\n* Presence of vision and\u002For hearing problems that prevent completion of relevant tests;\n* Alcohol or drug abuse\u002Fdependence;\n* Pregnancy;\n* Those who have participated or are participating in other clinical studies 3 months ago;\n* Failure or refusal to sign the informed consent form.",{"count":128,"type":21},60,[24],"The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia.\n\nSchizophrenic patients will receive treatment (Hi-tACS or shame stimulation) for 2 weeks.\n\nNegative symptoms, cognitive functioning, social functioning, and quality of life of intervention group and control group were assessed and compared between the two groups at baseline, 2 weeks, and 3 months post-intervention.",[132,27],"Schizophrenia; Negative Type",[134,135,136,137],"Hi-tACS","Schizophrenia","Randomized Controlled Trial","Negative symptoms","2025-05-29",{"date":140,"type":33},"2025-06-04",{"date":142,"type":33},"2024-06-27",{"date":144,"type":21},"2026-11-30",{"name":146,"class":40},"Shanghai Mental Health Center",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":41},"100559516","effect-of-transcranial-alternating-current-stimulationtacs-for-early-alzheimers-disease-100559516","NCT06565143","Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease","Inclusion Criteria:\n\n1. Subject diagnosed with early Alzheimer's disease or related diseases according to NIA-AA criteria.\n2. Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia.\n3. CDR score ≤ 2.\n4. Subject under treatment by IAChE for at least 3 months.\n5. psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months.\n\nExclusion Criteria:\n\n1. CDR \\> 2\n2. Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).\n3. History of head injury,stroke,or other neurologic disease.\n4. Organic brain defects on T1 or T2 images.\n5. History of seizures or unexplained loss of consciousness.\n6. Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.\n7. Family history of medication refractory epilepsy.\n8. History of substance abuse within the last 6 months.","50 Years","85 Years",{"count":52,"type":21},[24],"To investigate the clinical effect neural mechanism of transcranial alternating current stimulation in early Alzheimer's disease",[27,159,160],"Electroencephalography","Early Alzheimer's Disease",[27,159,162,160,163,164],"Neuropsychology","Alzheimer's Disease Assessment Scale-Cognitive Subscale","Working Memory","2024-08-19",{"date":167,"type":33},"2024-08-21",{"date":169,"type":33},"2024-03-01",{"date":171,"type":21},"2026-07-01",{"name":173,"class":40},"Anhui Medical University"]